ArticleHereditas2026
Clinical relevance and mechanistic investigation of miR-1908-5p as a prognostic biomarker in colorectal cancer.
Article in Hereditas, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundColorectal cancer (CRC) is characterized by a complex pathogenesis and substantial heterogeneity in prognosis.
objectiveThis study aims to elucidate the clinical significance of miR-1908-5p in CRC, as well as its association with clinicopathological parameters and patient prognosis.
methodmiR-1908-5p expression in tumor tissues was quantified by RT-qPCR. Survival outcomes were assessed using the Kaplan-Meier method. The chi-square (χ
resultsmiR-1908-5p is downregulated in CRC tumors versus adjacent normal mucosal tissues. Low expression predicts poor prognosis and is associated with reduced survival rates in colorectal cancer, correlating with advanced TNM stage and elevated serum CA19-9 levels. CRC lines (HT-29 and HCT116) show reduced miR-1908-5p compared to NCM460. miR-1908-5p mimic suppresses proliferation, migration, and invasion. TargetScan-predicted binding to SCAMP4 3'-UTR was validated by dual-luciferase reporter assay. miR-1908-5p overexpression lowers SCAMP4, which is overexpressed in tumor tissues and exhibits an inverse correlation with miR-1908-5p.
conclusionmiR-1908-5p is downregulated in CRC, correlates with TNM stage, nodal metastasis, elevated CA19-9 levels, and poor survival, and suppresses CRC cell proliferation, migration, and invasion by directly targeting SCAMP4, thereby qualifying as a potential prognostic biomarker for CRC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.